Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
22.8.2023 15:30:00 EEST | Business Wire | Press release
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, has announced that its collaborative work with HanX Biopharmaceutical Co., Ltd. (“HanX”), employing a unique and broad portfolio of preclinical modeling in support of HanX’s successful FDA Investigational New Drug (IND) application, has been published in Scientific Reports, a journal within the Nature portfolio.
The study demonstrated that HX009, an investigational “first-in-class” PD-1 x CD47 bispecific antibody, binds differentially to both PD-1 and CD47 with strong affinity to PD-1 but weakened affinity to CD47. This feature enables better targeting to the tumor microenvironment (TME) and minimizes potential hematological toxicity. In addition, HX009 exhibited enhanced T-cell activating capability over HX008, an approved and marketed anti-PD-1 monoclonal antibody in China.
Specifically, this new study showed that HX009 exerted robust anti-lymphoma activity in two cell-derived xenograft (CDX) models (Raji B-lymphoma and Karpas-299 T-lymphoma) with high CD47 expression. Additionally, custom patient-derived xenograft (PDX) models established by Crown Bioscience, further confirmed the efficacy of CD47 targeting by HX009. In addition, an A20-hCD47 mouse B-lymphoma model developed in hSIRPα/hCD47/PD-1/PD-L1 quadruple knock-in genetically engineered mouse models (HuGEMMTM ) mice, HX009 exhibited superior anti-lymphoma efficacy compared to CD47 or PD-1 targeting alone. These results imply a synergy between CD47 and PD-1 dual targeting.
These Crown Bioscience studies played an important role in supporting the application of HX009 for the treatment of lymphoma in clinical trials. They also played an instrumental role in supporting the clearance of HanX’s FDA Investigational New Drug (IND) application, which has paved the way for a U.S.-based Phase I/II clinical study that will assess HX009 in the treatment of relapsed/refractory lymphoma.
This exciting result exemplifies the value that Crown Bioscience brings to its partners as they seek better solutions for advancing their oncology research. Specifically, the collaboration between scientists from both organizations, utilizing an integrated solution approach, leveraged a comprehensive collection of preclinical and translational studies to investigate the anti-lymphoma activity of HX009.
While HX009 has been studied in Phase I clinical studies in Australia and China in both solid tumor and lymphoma indications, HanX is now expanding the next phase of clinical development globally in a variety of clinical indications.
Henry Li, PhD, Cofounder, Chief Executive Officer and Chief Scientific Officer of HanX, stated: “We are delighted with the exceptional outcomes of our partnership with Crown Bioscience. By leveraging a wide breadth of in vivo solutions such as cell-derived xenograft (CDX), patient-derived xenograft (PDX), and genetically engineered mouse models, together with translational applications, we were able to conduct a comprehensive evaluation of HX009’s anti-lymphoma activity prior to clinical trials.”
Ludovic Bourre, PhD, VP, Research and Innovation at Crown Bioscience, added: “Our commitment goes beyond identifying the right candidate drug or drug combination. Crown Bioscience consistently invests in expanding the number and diversity of models for drug development, ensuring that our models accurately represent the relevant clinical disease biology and provide a solid foundation for making informed decisions about novel therapeutics such as HanX's HX009.”
This work has laid a robust foundation for the advancement of HX009 as a highly promising therapeutic agent in the treatment of relapsed/refractory lymphoma. To learn more, Crown Bioscience and HanX are hosting an exclusive webinar on Tuesday August 29, 2023, where a team of scientists will discuss the implications of the study. The webinar will provide a unique opportunity to engage with the experts.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology, immuno-oncology, and immune-mediated inflammatory diseases. We are the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology. In addition, we have developed the largest commercially available PDX collection in the world. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 14 facilities across the United States, Europe, and Asia.
For more information or to get in touch, please visit www.crownbio.com
About HanX
HanX is a global biopharmaceutical company that develops innovative immuno-oncology antibody-based drugs, such as novel BsAb antibodies to address significant unmet medical needs. HanX brings together experts from both China and the U.S., to aid in activities ranging from early discovery, process development, business development, and clinical research. The company aims to accomplish its ambitious goals by relying on in-house research and development in combination with external global collaborations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230822704578/en/
Contact information
Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Deepens Private Client Tax Capabilities with KTA Tax15.10.2026 16:30:00 EEST | Press release
Andersen Global broadens its private client tax capabilities through a Collaboration Agreement with KTA Tax, a Dublin-based tax practice that has advised individuals and families for nearly three decades. KTA Tax has advised private clients and their families since 1997, combining the personal approach of a boutique practice with deep technical knowledge of Irish taxation. Its services span transaction and tax planning, estate planning, investments and pensions, cross-border matters, Revenue interventions, employment tax, and annual personal tax compliance. “We have remained focused on one thing: providing clear, thoughtful tax advice that reflects the individual circumstances of our clients and their families,” said Lisa Cantillon, CEO of KTA Tax. “Collaborating with Andersen Global is an important step for KTA Tax, giving us an opportunity to build on that foundation while extending the resources available to the clients we serve.” “Private client work demands an understanding of mor
Sysco Awards Partner of the Year Award to Grid Dynamics15.10.2026 16:15:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”) today announced that Sysco, the global foodservice distribution leader, has named the company its Partner of the Year. The recognition honors Grid Dynamics’ approach and expertise in bringing AI into Sysco’s technology and business operations. Sysco is the global leader in foodservice distribution, generating $84.6 billion in sales for its fiscal year ended June 27, 2026, and serving approximately 670,000 customer locations across 10 countries. The partnership began in 2024 with Grid Dynamics teams working alongside Sysco across product search and discovery, digital commerce, and AI-first software development. Grid Dynamics delivered a range of projects that made everyday work easier for Sysco's associates, enhanced the customer experience, and generated measurable business value. “What makes this partnership work is how closely our teams operate together,” said Ragnarok Rocha, Vice President, Digital Commerce and Customer S
The Outcome Economy at Work – New Research From Vertage15.10.2026 16:01:00 EEST | Press release
Three in four enterprises (74%) define significant work around outcomes, but only 15% are ready to deliver it consistently, according to new global research from HR tech leader Vertage. These ‘outcome-ready’ enterprises report higher customer satisfaction (91% vs. 67%), stronger delivery of strategic goals (86% vs. 65%) and faster conversion of opportunities into value (85% vs. 64%). They also have a cultural edge: 69% of their employees understand their contribution and can adapt how they work, compared with 34% elsewhere. "AI adoption no longer separates strong businesses from the rest. Outcome readiness does," said Edzard Overbeek, Group CEO of Vertage. "The strongest businesses organize people, partners and AI around a clear result, and they keep human judgment at the center." The study, The Outcome Economy at Work, draws on 800 enterprise decision-makers and 1,200 workers across six markets, plus in-depth interviews with senior leaders. Its central finding is clear: outcome-based
Introducing Ledger Atom™—Everything You Value, Finally Secure15.10.2026 15:45:00 EEST | Press release
Ledger™, the global leader in secure infrastructure for digital ownership, today unveiled Ledger Atom™, a security and privacy device that runs your everyday apps, purpose-built to help protect your money, your AI agent approvals, and your privacy. The innovative architecture of Ledger Atom, leveraging Android™ open source alongside Ledger OS™, Ledger’s proprietary security-first operating system running on a secure element chip, allows you to approve sensitive actions in a secure environment while using all your everyday apps on a single device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015445765/en/ Ledger has launched Ledger Atom, a security and privacy device that runs your everyday apps, purpose-built to help protect your money, your AI agent approvals, and your privacy. Your phone is not secure, and threats targeting it are escalating; mobile zero-days nearly doubled year over year in 2025, and commercial spywa
Meet Yuvo - The All-In-One Platform Helping Travel Brands Optimize Every Stage of Their Customer's Journey15.10.2026 15:36:00 EEST | Press release
Yuvo data shows that flight disruption hit more than 913 million passengers in 2025, and travellers are now buying travel protection at six times the pre-pandemic rate. Yet for most travel brands, a delayed flight still means support calls, refunds and lost customers. Yuvo turns those moments, and every other step of the trip, into revenue and loyalty. Most travel brands earn from their customers only once: when they book. Yuvo changes that. It helps partners earn across the whole journey, with no technology to build and full control of the customer relationship. Yuvo works with some of the biggest names in travel, turning the customer relationships they already have into an ongoing revenue stream while keeping them fully in control. Built by a team of seasoned travel tech experts, the platform has already helped more than 26 million travelers through its services, improving customer experience and building loyalty worldwide. Yuvo’s Services - adding value at every stage of the journey
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom